Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose decitabine in chronic myelomonocytic leukemia
ChiCTR-OPC-17010598Phase 4Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of decitabine in chronic myelomonocytic leukemia (CMML), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: overall response rate. Planned start Mar 2017; status: not yet recruiting.
02
Drugs
decitabine
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on ChiCTR-OPC-17010598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17010598.